Background: Locoregional failure is common after subtotal resection in high-risk neuroblastoma.
INTRODUCTION
Neuroblastoma is the most common extracranial solid tumor in children, with 650 new cases per year in the USA (50% of which are highrisk). Multiple studies have shown a benefit of radiation therapy (RT) to the primary site after chemotherapy and surgical resection in highrisk disease. [1] [2] [3] Our institution and others have previously shown that a dose of 21 Gy RT provides excellent local control after gross total resection (GTR). [4] [5] [6] [7] Although local failure (LF) is <10% among patients treated with 21 Gy RT after GTR, locoregional recurrence is much Abbreviations: CTV, clinical target volume; EFS, event-free survival; GTR, gross total resection; LF, local failure; MSK, Memorial Sloan Kettering; OS, overall survival; RT, radiation therapy more common among patients with macroscopic residual disease after surgical resection, with local recurrence rates approaching 50%. 8 There are no randomized trials that have directly addressed the role and optimal dose of RT to the primary site in high-risk neuroblastoma. Consequently, the dose needed for control of macroscopic residual disease after subtotal resection is not known. Modern protocols recommend treatment with 36 Gy for gross residual disease, given prior reports suggesting a dose-response relationship, 9 but this dose was empirically derived. As children with high-risk neuroblastoma are now living longer with the addition of differentiation therapy and antibody treatment, local control at the primary site becomes more critical. In addition, with an increase in survival, long-term toxicity associated with intensified chemoradiation becomes more of a concern.
We sought to evaluate the rate of local control after 21-36 Gy RT in patients with high-risk neuroblastoma undergoing subtotal resection Other* 1 * 12 Gy total body irradiation followed by 12.6 Gy to the primary site 5 months later.
at a single institution with a large number of patients treated with a range of radiation dose levels, with the secondary goal of evaluating the necessary dose for optimal control of gross residual disease.
METHODS
This is a single institution, retrospectively ascertained cohort of all neu- 
Treatment
Seven patients (37%) were treated on or according to MSK induction chemotherapy protocols N7 (n = 1) and N8 (n = 6), 10 and 11 patients (58%) were treated on or according to COG, POG, SIOP, or other institutional protocols. The choice of chemotherapy protocol was based on timing and the institution at which the patient started systemic therapy. One patient received standard chemotherapy off of protocol in Brazil. Following induction chemotherapy, all patients but one underwent surgical resection (this patient did not due to parental and external medical oncologist concern for potential risks of resection).
As part of consolidative therapy, all patients received RT to the primary site at a median time of 8.8 months from initiation of chemotherapy. See Table 1 
Statistical analysis
LF was defined as relapse in the primary tumor bed and/or regional nodes. Imaging at the time of recurrence was compared with RT treatment plans to evaluate if the recurrence occurred within the RT field. A competing-risks analysis was used to assess the cumulative incidence of LF, with competing events including distant failure and/or death.
Event-free survival (EFS) was calculated as the time from initiation of induction chemotherapy to disease progression, including local and/or distant relapse. Overall survival (OS) was calculated as the time from induction to death from any cause. Patients without an event were censored at the time of last follow up. The Kaplan-Meier method was used to evaluate the EFS and OS.
RESULTS
See Table 2 
Local relapse
Three patients relapsed locally at a median time of 1.1 years (range, 0.4-1.5 years) from RT. All local relapses occurred within the radiation field. See Figure 1 for an example of an in-field local relapse.
The 5-year cumulative incidence of LF was 17.2%. LF was 30.0% in those who received <30 Gy versus 0% in those who received ≥30 Gy 
Survival outcomes
The 5-year EFS and OS were 44.9% and 68.7%, respectively. Survival outcomes were higher among patients who received ≥30 Gy (5-year 5-year EFS and OS were 54.2% and 68.4% in patients without local recurrence versus and 0% and 33% in those with local recurrence.
DISCUSSION
As induction chemotherapy has intensified, the ability to achieve GTR has improved. GTR in turn has been correlated with improved outcomes. 8, 11 However, due to anatomical constraints (for example, encasement of abdominal vessels and involvement of neural foramina), GTR is not feasible in all, and locoregional failure is frequent among this subset of patients. In a cohort of patients treated at our institution from 1972-2002, local control and OS were 90% and 50% in patients who achieved GTR versus 50% and 11% in those who did not. 8 (Table 3) . 5, 7, [12] [13] [14] Thus, it appears that the current recommendation on modern protocols for 36 Gy is not only appropriate but likely necessary for optimal local control of macroscopic disease.
TA B L E 3
On the NB97 trial, RT with 36-40 Gy was reserved for patients with local residual disease. Of the 36 patients with gross residual disease after surgery, only 13 went on to receive RT as recommended. influence on survival. 12 We similarly found that survival outcomes were higher in patients who were treated with ≥30 Gy and did not experience local relapse, although this was not statistically significant in our small cohort. Our results further reinforce the importance of dose-escalated radiotherapy to macroscopic disease in achieving long-term disease control in high-risk neuroblastoma. Importantly, as metastatic disease control improves with advancements in systemic and targeted agents, the benefit of local control at the primary site will become more apparent.
Limitations of this analysis include its retrospective nature and small numbers. In addition, our surgical outcomes (with a GTR rate of approximately 95%) may not be representative of outcomes at other treatment centers where aggressive surgical resection for neuroblastoma is not routinely performed. Our surgical outcomes as well as our specialized pediatric oncologists and radiation oncologists likely influence our results and limit the generalizability of our findings. Furthermore, we were unable to analyze whether the type of induction therapy or chemotherapy protocol had an effect on outcomes, given our small numbers.
In summary, our results suggest that 30-36 Gy is necessary for local control of gross disease in high-risk neuroblastoma. The most recent neuroblastoma COG protocol ANBL0532 mandated a dose of 21.6 Gy to the preoperative tumor volume with a 14.4 Gy boost to any gross residual disease. The local control rates of patients treated with 36 Gy on this protocol will be compared to a historical cohort of patients treated with 21 Gy on COG A3973. Ultimately, the results of this study will be instrumental in determining the optimal dose of RT needed for macroscopic disease control in high-risk neuroblastoma.
